Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Int J Cancer ; 93(3): 393-400, 2001 Aug 01.
Artigo em Inglês | MEDLINE | ID: mdl-11433405

RESUMO

For gene therapy to be effective in cancers, it is necessary to deliver therapeutic genes into cells with high specificity and efficiency. In this study, we examined the in vitro and in vivo gene delivery efficiency of a new, growth receptor-mediated gene transfer system in hepatocellular carcinoma (HCC). The effects of transfection of wild-type p53 using this system were also studied. The system consisted of a ligand oligopeptide for epidermal growth factor receptor (EGFR) recognition, a polypeptide for DNA binding, and an endosome-releasing oligopeptide for endosomolysis. Two human HCC cell lines and a normal liver cell line were used, and pCMV-beta-galactosidase (beta-gal) was used as a reporter gene. Both HCC cell lines had strong expression of EGFR and the in vitro transfer efficiency peaked at day 5 at about 50%. This finding was in contrast to the normal liver cell line, which had weak EGFR expression and less than 1% transfer efficiency throughout. For in vivo gene transfer in tumors produced by inoculating HCC cells in nude mice and with the vector-beta-gal gene complex injected peritumorally, beta-gal expression was detected within the tumors at 12 hr, peaked at day 5 involving about 50% of the tumor cells and persisted at 2 weeks. Using this vector system, transfection of wild-type p53 into Huh-7 cells that had mutated p53 resulted in significant growth inhibition of cancer cells accompanied by a decreased G2/M phase and increased p53 protein. In conclusion, this receptor-mediated gene transfer system appears to work specifically in HCC cells with high efficiency, and may be promising in delivering apoptotic and other genes into HCC cells.


Assuntos
Carcinoma Hepatocelular/terapia , Receptores ErbB/genética , Genes p53 , Terapia Genética/métodos , Neoplasias Hepáticas/terapia , Retroviridae/genética , Antineoplásicos/uso terapêutico , Apoptose , Western Blotting , Carcinoma Hepatocelular/metabolismo , DNA/química , Receptores ErbB/metabolismo , Citometria de Fluxo , Expressão Gênica , Hemaglutininas/metabolismo , Humanos , Neoplasias Hepáticas/metabolismo , Oligopeptídeos/metabolismo , Transfecção , Células Tumorais Cultivadas , beta-Galactosidase/metabolismo
2.
Sci Sin B ; 29(2): 173-80, 1986 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-3018922

RESUMO

DNA was extracted from NIH 3T3 cells transformed with DNAs from human primary hepatic cancer (PHC) and Hepatoma 7402 cell line. The transformant DNA was analyzed by Southern transfer and hybridization with 32P-labeled probes of various oncogenes. The EcoRI 7.2 and 9.0 kb bands characteristic of human N-ras gene were identified in transformed NIH 3T3 cells derived both from PHC and 7402 DNA. The BamHI 6.6 kb band characteristic of human c-Ha-ras I was present only in 7402 transformants, but not in PHC transformants. Using 35S-methionine incorporation, immunoprecipitation with anti-p21 monoclonal antibodies, SDS-PAGE and autoradiography, it was demonstrated that p21 synthesis was remarkably enhanced in 7402 cells as well as in transformed cells derived from both 7402 and PHC DNA. Taking the data together, it strongly implies that N-ras is one of the transforming genes for human liver cancer.


Assuntos
Carcinoma Hepatocelular/genética , DNA de Neoplasias/genética , Neoplasias Hepáticas/genética , Oncogenes , Animais , Linhagem Celular , Transformação Celular Neoplásica/análise , Humanos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...